CYLD and Parkinson disease: Similarly, the development of CYLD inhibitors for PD treatment may encounter challenges related to the PINK1/parkin pathway’s multifaceted nature, which regulates mitochondrial quality control and has implications for cellular homeostasis beyond neurodegeneration.